Ahn M.-JCHIH-HSIN YANGYu HSaka HRamalingam SGoto KKim S.-WYang LWalding AOxnard G.R.2020-05-262020-05-2620161556-0864https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040257501&doi=10.1016%2fS1556-0864%2816%2930246-5&partnerID=40&md5=2335223cd25d2e838545fb1d2dbf1f0chttps://scholars.lib.ntu.edu.tw/handle/123456789/494984[SDGs]SDG3corticosteroid; durvalumab; osimertinib; anemia; Article; cancer combination chemotherapy; clinical article; controlled clinical trial; controlled study; corticosteroid therapy; diarrhea; drug dose escalation; drug efficacy; drug safety; drug tolerability; EGFR gene; gene mutation; human; monotherapy; nausea; non small cell lung cancer; phase 1 clinical trial (topic); priority journal; receptor gene; vomiting136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trialjournal article10.1016/S1556-0864(16)30246-52-s2.0-85040257501